Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Chemoproteomics-enabled Development of Novel Cysteine and Serine Reactive Small Molecules: from Target Identification to Inhibitor Discovery

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

Comparative Reactivity Profiling of Cysteine-Specific Probes by Chemoproteomics

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

Applications of covalent chemistry in targeted protein degradation

Chemoproteomics and Chemical Probes for Target Discovery

An immuno-chemo-proteomics method for drug target deconvolution

Catalyst-Free Late-Stage Functionalization to Assemble α-acyloxyenamide Electrophiles for Selectively Profiling Conserved Lysine Residues

Discovery of a Tunable Heterocyclic Electrophile 4-Chloro-pyrazolopyridine That Defines a Unique Subset of Ligandable Cysteines

Delineating cysteine-reactive compound modulation of cellular proteostasis processes

Chemoproteomics: Towards Global Drug Target Profiling

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Chemical proteomic mapping of reversible small molecule binding sites in native systems

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

[Chemical Proteomics and Discovery of Drug Targets].

Discovery of Non-Cysteine-Targeting Covalent Inhibitors by Activity-Based Proteomic Screening with a Cysteine-Reactive Probe.

Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development